Entries by Uta Mommert

EMA unveils trial data

Trial transparency has been a hotly debated topic over the last months, but now, the EMA is turning words into action. The agency will allow public access to clinical trial reports, starting now.

Dilaforette: Going public with a new name

New name, new outlook: blood disorder specialist Dilaforette will be known as Modus Therapeutics Holding from here on out. The Swedish company also announced an intention to float in the near future.

Ysios closes €126m BioFund

Spanish start-ups, take heed: One of the biggest biotech funds in Southern Europe has just been closed by Ysios Capital. The Spanish venture firm raised €126.4m to be reinvested in European biotech, medtech and diagnostics companies. 

Diabetes giant cuts jobs

Danish insulin maker Novo Nordisk tries to relieve financial pressure by laying off 1,000 staff. The step was necessary due to challenges on the US market, the company said.

BioNTech teams up with Genentech

German immuno-oncology play BioNTech has entered into a collaboration with Roche’s Genentech to develop novel mRNA-based, individualised cancer vaccines. The deal will net BioNTech €278m.

With PhI win, Prexton targets Phase II

Prexton Therapeutics is taking aim at Phase II: The Swiss company happily presented results for its Phase I trial of its mGluR4 positive allosteric modulator in Parkinson’s Disease, saying the first-in-class compound proved to be safe and well tolerated.

Novozymes bags Organobalance

Denmark’s Novozymes has acquired microbial research company Organobalance GmbH. The German company owns a large collection of microbial strains, some of which date back to the 1920s, and has strong capabilities in microbial screening and assay technology.

AC Immune boldly prices Nasdaq IPO

14.09.2016 – The summer slump on the stock markets is over: AC Immune has confidently priced its long-awaited Nasdaq IPO. The Swiss Alzheimer’s specialist is expecting to raise up to US$68m (€60.5m) overseas.

Sanofi, Google launch diabetes venture

13.09.2016 – Diabetes major Sanofi is joining forces with Verily – formerly Google Life Sciences – to launch Onduo. The joint venture will develop a comprehensive diabetes management platform.